Aims of Seroxat User Group

To notify individuals who take Seroxat and who desire to withdraw from the drug with the means and methods to do so.

Provision for the accumulation and analysis of relevant medical facilities that can withdraw Seroxat from users safely.

Provision for the individual funding of safe Seroxat withdrawal.

Provision of medical research concerning any long term effects of Seroxat.

Compensation, where appropriate, for individuals who have suffered with the drug.

Many patients using Seroxat have found that:

• During treatment Seroxat can cause psychiatric problems that previously were not there and in some cases this has led to violent behaviour towards others and suicide.
  
• The drug causes dependency (despite claims to the contrary) the withdrawal from which has caused the occurrence of new symptoms and an exacerbation of previous symptoms.

Seroxat was said by SmithKline Beecham to be non-addictive. However patients worldwide have described serious and long term side effects that make it very difficult to come off the drug after using it for as little as two days. Other complaints include the development of aggressive tendencies.

Concern over the drug has gained momentum since June 2001 when a jury in USA ordered GSK, in what has become known as the Schell cases, to pay substantial damages $6.4million (£4.6million) to the family of a man who killed his wife, children and then himself after he had taken Paxil (the American trading name of Seroxat) for just two days.

A World Health Organisation league table of the drugs that have difficulties on withdrawal puts Paroxetine (Seroxat) at the top with twice as many reports as the next highest, another SSRI called Efexor (Venlafaxine). The benzodiazapines Ativan and Valium rate 11th and 13th . The World Health Organisation has said there is ‘a need for repeated doses of the drug to feel good or avoiding feeling bad.'